BRISBANE, Calif., June 05, 2024 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical firm advancing a late-stage scientific platform of novel therapies for folks residing with devastating classical complement-mediated neuroinflammatory illnesses of the physique, mind, and eye, in the present day introduced the pricing of its beforehand introduced underwritten public providing of 13,001,120 shares of its widespread inventory at a worth to the general public of $6.25 per share and, in lieu of widespread inventory to sure traders, pre-funded warrants to buy 7,000,000 shares of widespread inventory at a purchase order worth of $6.249 per share, which equals the general public providing worth per share of the widespread inventory much less the $0.001 train worth per share of every pre-funded warrant.
The overall gross proceeds to Annexon are anticipated to be $125.0 million, earlier than deducting underwriting reductions and commissions and different providing bills payable by Annexon. The providing is anticipated to shut on June 7, 2024, topic to the satisfaction of customary closing situations. As well as, Annexon has granted the underwriters a 30-day choice to buy as much as an extra 3,000,168 shares of widespread inventory.
J.P. Morgan, Jefferies, TD Cowen, BofA Securities and Wells Fargo Securities are appearing as joint book-running managers for the providing.
The shares are being provided by Annexon pursuant to a shelf registration assertion on Kind S-3, together with a base prospectus, that was filed with the Securities and Trade Fee (SEC) and declared efficient by the SEC on April 1, 2024. The providing is being made solely by way of a prospectus complement and the accompanying prospectus that may type part of the registration assertion. These paperwork might be accessed free of charge by the SEC’s web site at www.sec.gov. Copies of the ultimate prospectus complement and the accompanying prospectus, when accessible, could also be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Monetary Options (NYSE:), 1155 Lengthy Island Avenue, Edgewood, NY 11717, or by e-mail at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or Jefferies LLC, Consideration: Fairness Syndicate Prospectus Division, 520 Madison Avenue, New York, NY 10022, by phone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com; or TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by phone at (855) 495-9846, or by e-mail at TD.ECM_Prospectus@tdsecurities.com; or BofA Securities, NC1-022-02-25, 201 North Tryon Road, Charlotte, NC 28255, Consideration: Prospectus Division, or by e-mail at dg.prospectus_requests@bofa.com; or Wells Fargo Securities, 90 South seventh Road, fifth Flooring, Minneapolis, MN 55402, by phone at 800-645-3751 (possibility #5), or by e-mail at WFScustomerservice@wellsfargo.com.
This press launch shall not represent a proposal to promote or the solicitation of a proposal to purchase nor shall there be any sale of those securities in any state or jurisdiction wherein such a proposal, solicitation or sale can be illegal previous to registration or qualification below the securities legal guidelines of any such state or jurisdiction.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is a biopharmaceutical firm advancing a late-stage scientific platform of novel therapies for folks residing with devastating classical complement-mediated neuroinflammatory illnesses of the physique, mind, and eye. Annexon’s novel scientific strategy targets upstream C1q to dam the classical complement inflammatory cascade earlier than it begins, and its therapeutic candidates are designed to supply significant advantages throughout a number of autoimmune, neurodegenerative and ophthalmic illnesses. With proof-of idea information in Guillain-Barré syndrome, Huntington’s illness and geographic atrophy, Annexon is rigorously advancing its mid-to late-stage scientific trials to convey new potential therapies to sufferers as shortly as potential.
Ahead-Trying Statements
This press launch incorporates forward-looking statements throughout the that means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Trade Act of 1934, as amended. In some instances, you may establish forward-looking statements by terminology resembling purpose, anticipate, assume, imagine, ponder, proceed, might, design, due, estimate, anticipate, aim, intend, could, goal, plan, positioned, potential, predict, search, ought to, counsel, goal, on observe, will, would and different related expressions which can be predictions of or point out future occasions and future developments, or the destructive of those phrases or different comparable terminology. All statements aside from statements of historic details contained on this press launch are forward-looking statements. These forward-looking statements embrace, however will not be restricted to, statements in regards to the anticipated gross proceeds from the providing and the deadline of the providing. Ahead-looking statements will not be ensures of future efficiency and are topic to dangers and uncertainties that might trigger precise outcomes and occasions to vary materially from these anticipated, together with, however not restricted to, dangers and uncertainties associated to, amongst different issues, market situations and the satisfaction of customary closing situations associated to the general public providing. These and different dangers are described in larger element below the part titled Threat Elements contained within the preliminary prospectus complement and the accompanying prospectus, the corporate’s Annual Report on Kind 10-Ok and Quarterly Reviews on Kind 10-Q and the corporate’s different filings with the SEC. Any forward-looking statements that the corporate makes on this press launch are made pursuant to the Personal Securities Litigation Reform Act of 1995, as amended, and converse solely as of the date of this press launch. Besides as required by legislation, the corporate undertakes no obligation to publicly replace any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
Investor Contact:
Joyce AllaireLifeSci Advisorsjallaire@lifesciadvisors.com
Media Contact:
Sheryl SeapyReal Chemistry949-903-4750sseapy@realchemistry.com
Supply: Annexon Biosciences
